ADAR1 Capital Management LLC Makes New Investment in Pulmonx Corporation $LUNG

ADAR1 Capital Management LLC acquired a new stake in shares of Pulmonx Corporation (NASDAQ:LUNG - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 404,497 shares of the company's stock, valued at approximately $526,000. ADAR1 Capital Management LLC owned 0.94% of Pulmonx at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Primecap Management Co. CA purchased a new stake in shares of Pulmonx in the 2nd quarter worth about $5,996,000. ExodusPoint Capital Management LP purchased a new position in Pulmonx during the 4th quarter valued at about $4,312,000. BlackRock Inc. purchased a new position in Pulmonx during the 2nd quarter valued at about $1,147,000. Vestal Point Capital LP purchased a new position in Pulmonx during the 3rd quarter valued at about $1,345,000. Finally, Parkman Healthcare Partners LLC bought a new stake in Pulmonx during the second quarter worth about $841,000. Institutional investors own 91.04% of the company's stock.

Pulmonx Stock Performance

Shares of LUNG stock opened at $2.50 on Thursday. The company has a market capitalization of $107.38 million, a price-to-earnings ratio of -2.16 and a beta of 0.28. The company has a debt-to-equity ratio of 0.95, a quick ratio of 3.52 and a current ratio of 4.32. Pulmonx Corporation has a one year low of $1.13 and a one year high of $2.89. The company's 50-day moving average is $1.68 and its 200 day moving average is $1.53.

Pulmonx (NASDAQ:LUNG - Get Free Report) last issued its earnings results on Wednesday, July 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.04. The business had revenue of $22.76 million during the quarter, compared to analysts' expectations of $22.39 million. Pulmonx had a negative net margin of 55.03% and a negative return on equity of 96.66%. Sell-side analysts expect that Pulmonx Corporation will post -1.05 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Weiss Ratings raised Pulmonx from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday. D. Boral Capital reaffirmed a "buy" rating and set a $14.00 price objective on shares of Pulmonx in a research report on Thursday, April 30th. Finally, Wall Street Zen upgraded Pulmonx from a "sell" rating to a "hold" rating in a research note on Saturday, June 27th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $7.67.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company's flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.

Want to see what other hedge funds are holding LUNG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pulmonx Corporation (NASDAQ:LUNG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source